These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21041708)

  • 1. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.
    Alibhai SM; Breunis H; Timilshina N; Marzouk S; Stewart D; Tannock I; Naglie G; Tomlinson G; Fleshner N; Krahn M; Warde P; Canning SD
    J Clin Oncol; 2010 Dec; 28(34):5030-7. PubMed ID: 21041708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.
    Alibhai SM; Breunis H; Timilshina N; Johnston C; Tomlinson G; Tannock I; Krahn M; Fleshner NE; Warde P; Canning SD; Klotz L; Naglie G
    J Clin Oncol; 2010 Dec; 28(34):5038-45. PubMed ID: 21041715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
    Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
    J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer.
    Marzouk S; Naglie G; Tomlinson G; Duff Canning S; Breunis H; Timilshina N; Alibhai SMH
    J Urol; 2018 Aug; 200(2):327-334. PubMed ID: 29477720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
    Wassersug RJ; Wadhwa D
    Cancer; 2005 Nov; 104(9):2032-3; author reply 2033. PubMed ID: 16196043
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
    Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.
    Alibhai SM; Timilshina N; Duff-Canning S; Breunis H; Tannock IF; Naglie G; Fleshner NE; Krahn MD; Warde P; Marzouk S; Tomlinson GA
    Cancer; 2017 Jan; 123(2):237-244. PubMed ID: 27583806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer.
    Timilshina N; Breunis H; Alibhai S
    Cancer; 2012 Apr; 118(7):1940-5. PubMed ID: 22009684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
    Herr HW; O'Sullivan M
    J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Arch Intern Med; 2007 Mar; 167(6):612-3. PubMed ID: 17389294
    [No Abstract]   [Full Text] [Related]  

  • 20. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.